1153 related articles for article (PubMed ID: 25573334)
21. Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.
Gomez-Eerland R; Nuijen B; Heemskerk B; van Rooij N; van den Berg JH; Beijnen JH; Uckert W; Kvistborg P; Schumacher TN; Haanen JB; Jorritsma A
Hum Gene Ther Methods; 2014 Oct; 25(5):277-87. PubMed ID: 25143008
[TBL] [Abstract][Full Text] [Related]
22. Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity.
Andrews K; Hamers AAJ; Sun X; Neale G; Verbist K; Tedrick P; Nichols KE; Pereira S; Geraghty DE; Pillai AB
Cytotherapy; 2020 May; 22(5):276-290. PubMed ID: 32238299
[TBL] [Abstract][Full Text] [Related]
23. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
[TBL] [Abstract][Full Text] [Related]
24. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
Perna SK; Pagliara D; Mahendravada A; Liu H; Brenner MK; Savoldo B; Dotti G
Clin Cancer Res; 2014 Jan; 20(1):131-9. PubMed ID: 24097874
[TBL] [Abstract][Full Text] [Related]
26. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
27. T cell stimulation and expansion by SunTag-based clustering of anti-CD3/CD28 scFv.
Zhong K; Liu Z; Li H; Zhao S; Wang Y; Guo W; Zheng X; Yang H; Guo G; Zhou L; Xu J; Tong A
Aging (Albany NY); 2020 Jun; 12(11):11061-11070. PubMed ID: 32526703
[TBL] [Abstract][Full Text] [Related]
28. CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
Altvater B; Pscherer S; Landmeier S; Niggemeier V; Juergens H; Vormoor J; Rossig C
Clin Exp Immunol; 2006 Jun; 144(3):447-57. PubMed ID: 16734614
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
30. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2.
Yamaguchi Y; Ohta K; Shimizu K; Minami K; Noma K; Hihara J; Toge T
Anticancer Res; 2001; 21(1B):669-77. PubMed ID: 11299824
[TBL] [Abstract][Full Text] [Related]
31. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.
Fisher J; Abramowski P; Wisidagamage Don ND; Flutter B; Capsomidis A; Cheung GW; Gustafsson K; Anderson J
Mol Ther; 2017 May; 25(5):1234-1247. PubMed ID: 28341563
[TBL] [Abstract][Full Text] [Related]
32. T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
Lamers CH; van Steenbergen-Langeveld S; van Brakel M; Groot-van Ruijven CM; van Elzakker PM; van Krimpen B; Sleijfer S; Debets R
Hum Gene Ther Methods; 2014 Dec; 25(6):345-57. PubMed ID: 25423330
[TBL] [Abstract][Full Text] [Related]
33. Effect of interleukin-15 on effector and regulatory function of anti-CD3/anti-CD28-stimulated CD4(+) T cells.
Lin SJ; Cheng PJ; Hsiao SS
Bone Marrow Transplant; 2006 May; 37(9):881-7. PubMed ID: 16565741
[TBL] [Abstract][Full Text] [Related]
34. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.
Krause A; Guo HF; Latouche JB; Tan C; Cheung NK; Sadelain M
J Exp Med; 1998 Aug; 188(4):619-26. PubMed ID: 9705944
[TBL] [Abstract][Full Text] [Related]
35. Effect of interleukin-15 on anti-CD3/anti-CD28 induced apoptosis of umbilical cord blood CD4+ T cells.
Lin SJ; Yu JC; Cheng PJ; Hsiao SS; Kuo ML
Eur J Haematol; 2003 Dec; 71(6):425-32. PubMed ID: 14703692
[TBL] [Abstract][Full Text] [Related]
36. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
37. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
Hombach AA; Rappl G; Abken H
Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
[TBL] [Abstract][Full Text] [Related]
38. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
39. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
40. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
Oluwole OO; Davila ML
J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]